Highlights TFF Pharmaceuticals, Inc.

Equities

TFFP

US87241J2033

Delayed Nasdaq Other stock markets 09:30:00 2024-07-09 am EDT			5-day change	1st Jan Change
1.89 ^USD	-3.08%		+6.18%	-73.08%

Jul. 01	TFF Pharmaceuticals, Inc Announces Resignation of Michael Patane from its Board of Directors	CI
Jul. 01	Certain Warrants of TFF Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 1-JUL-2024.	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Tff Pharmaceuticals, Inc. Provides Regulatory Update on Tacrolimus Inhalation Powder (Tff Tac) Clinical Program for the Prevention of Lung Transplant Rejection	Jun. 24	CI
TFF Pharmaceuticals, Leidos to Advance Biodefense Countermeasures Into Preclinical Testing	May. 23	MT
TFF Pharmaceuticals, Inc. and Leidos to Advance Next-Generation Biodefense Countermeasures Under the DARPA PPB Program into Preclinical Testing	May. 23	CI
TFF Pharmaceuticals Advances Influenza Vaccine Candidates Into Preclinical Testing	May. 20	MT
TFF Pharmaceuticals and Cleveland Clinic to Advance Multivalent Universal Influenza Vaccine Candidates into Preclinical Testing	May. 20	CI
Tff Pharmaceuticals, Inc. Provides Update on Tacrolimus Inhalation Powder (Tff Tac) Phase 2 Trial for the Prevention of Lung Transplant Rejection	May. 15	CI
TFF Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 14	CI
TFF Pharmaceuticals Prices $4.8 Million Public Offering; Shares Down Pre-Bell	Apr. 30	MT
TFF Pharmaceuticals, Inc. Makes Available Phase 2 Data from Tacrolimus Inhalation Powder for Prevention of Lung Transplant Rejection Presented at Recent ISHLT Annual Meeting	Apr. 29	CI
TFF Pharmaceuticals, Inc. Announces Additional Positive Data from the Tacrolimus Inhalation Powder (TFF Tac) Phase 2 Trial Following Oral Presentation At the Ishlt 44Th Annual Late-Breaking Clinical Science Abstract Sessions	Apr. 15	CI
Earnings Flash (TFFP) TFF PHARMACEUTICALS Reports Q4 Revenue $114.3M	Mar. 28	MT
TFF Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 28	CI
TFF Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
TFF Pharmaceuticals, Inc. Announces Updated Data from the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (Tff VORI) Clinical Programs	Mar. 27	CI
TFF Pharmaceuticals Sells Stock in Registered Direct Offering	Mar. 20	MT
TFF Pharmaceuticals, Inc. Announces Update on Clinical Programs	Mar. 20	CI
TFF Pharmaceuticals, Inc. to Present Data from Phase 2 Trial of Voriconazole Inhalation Powder for the Treatment of Invasive Pulmonary Aspergillosis At the 11Th Advances Against Aspergillosis & Mucormycosis & Mucromycosis Conference	Jan. 24	CI
TFF Pharmaceuticals, Inc. Announces Positive Initial Data from Ongoing Phase 2 Trials of TFF VORI and TFF TAC	Dec. 19	CI
TFF Pharmaceuticals, Inc. Appoints Thomas B. King to Board of Directors	Dec. 13	CI
TFF Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights TFF Pharmaceuticals, Inc.

Equities

TFFP

US87241J2033

Highlights

Filters